Pittsburgh, United States
CytoAgents, Inc, a promising Biotechnology and Health Care company based in the United States, was founded in 2018 with the mission of tackling Cytokine Release Syndrome (CRS). This clinical stage company is innovating the treatment of severe immune responses using its lead drug candidate, GP1681. By focusing on a novel approach to calm the immune system, CytoAgents aims to address multiple high unmet medical needs and potentially set a new standard in medical practice.
The company's tagline, “Calming the Cytokine Storm, Rebalancing the Immune System”, encapsulates its objective of developing accessible treatments for various conditions contributing to CRS. Recently, CytoAgents secured a $7.00M Series A investment, led by BlueTree Allied Angels and PCG Capital on 12 May 2023. This funding indicates strong investor confidence and supports the next stage of development for their groundbreaking treatments.
